期刊文献+

甲状腺滤泡性增生结节galectin-3和S100A4蛋白的表达

下载PDF
导出
摘要 目的:研究galectin-3和S100A4蛋白在良恶性甲状腺滤泡性增生结节中的表达情况。方法:采用免疫组织化学方法检测68例甲状腺滤泡性增生结节中galectin-3和S100A4蛋白的表达,包括17例滤泡性腺瘤、6例腺瘤性甲状腺肿、14例滤泡型乳头状癌和31例滤泡癌。结果:Galectin-3和S100A4在甲状腺滤泡性增生结节恶性组中的阳性率显著高于良性组(P<0.001)。滤泡癌与滤泡型乳头状癌组间比较,galectin-3表达差异有统计学意义(P=0.019)。结论:Galectin-3和S100A4蛋白可作为鉴别良恶性甲状腺滤泡性增生结节较有价值的肿瘤指标,galectin-3对滤泡癌与滤泡型乳头状癌的鉴别诊断具有参考意义。
出处 《实用医学杂志》 CAS 2008年第7期1156-1157,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献12

  • 1Papotti M, Rodriguez J, De Pompa R, et al. Galectin-3 and HBME- 1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential [J]. Mod Pathol, 2005, 18(4) :541-546.
  • 2吴文君,许岚,刘晓,朱圣炜,刘国萍,孙荣超,杨树东.Galectin-3在甲状腺乳头状癌中的表达及意义[J].实用医学杂志,2007,23(3):346-347. 被引量:4
  • 3顾学文,张真稳,陈月香,田秀春,朱长仁,肖芹.Galectin3、Cytokeratin19在甲状腺良恶性乳头状病变中的表达及临床意义[J].实用医学杂志,2005,21(12):1268-1269. 被引量:6
  • 4Laco J, Ryska A. The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern [J]. Cesk Patol, 2006,42 (3) : 120-124.
  • 5Ito Y, Yoshida H, Tomoda C, et al. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma [ J ]. Pathology, 2005,37 (4) : 296-298.
  • 6陈云,朱明华,周晓军,林万和,倪灿荣,李芳梅,张顺民,龚志锦.RET、Mucin1和Galectin-3在甲状腺良恶性肿瘤中的表达[J].第二军医大学学报,2003,24(3):303-306. 被引量:10
  • 7Zou M, Famulski K S, Parhar R S, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma [J]. Clin Endocrinol Metab, 2004, 89(12) :6146-6154.
  • 8Shi Y, Zou M, Collison K, et al. Ribonucleic acid interference iargeting S100A4 (Mts1) Suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model [J]. Clin Endocrinol Metab, 2006, 91 (6) : 2373-2379.
  • 9Garrett S C, Varney K M, Weber D J, et al. S100A4, a mediator of metastasis [ J ]. Biol Chem, 2006, 281 (2) : 677-680.
  • 10Saleem M, Kweon M H, Johnson J J, et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9 [ J ]. Proc Natl Acad Sci USA, 2006,103(40) : 14825-14830.

二级参考文献31

  • 1王丽华,赵咏桔,王晓颖,郑林,肖家诚,徐锦屏,罗邦尧.Galectin-3蛋白在甲状腺肿瘤中的表达及其意义[J].中华内分泌代谢杂志,2004,20(4):300-302. 被引量:6
  • 2顾学文,张真稳,陈月香,田秀春,朱长仁,肖芹.Galectin3、Cytokeratin19在甲状腺良恶性乳头状病变中的表达及临床意义[J].实用医学杂志,2005,21(12):1268-1269. 被引量:6
  • 3纪小龙,缪德标,李维华.无色素性恶性黑色素瘤的形态多样性[J].诊断病理学杂志,1995,2(4):201-202. 被引量:21
  • 4欧阳电,陈福进,魏茂文,杨安奎,陈振清,李秋梨,陈艳峰.Galectin-3在分化型甲状腺癌细胞中的表达及其临床意义[J].癌症,2005,24(11):1367-1371. 被引量:4
  • 5Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology, 2002, 41 (3): 236 - 243.
  • 6Ohannesian DW, Lotan D, Thomas, et al. Carcinoembryonic antigen and other glycoconiugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res, 1995, 55 (10): 2191 - 2199.
  • 7Faggiano A, Talbot M, Lacroix L, et al. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol, 2002, 57(6): 813 - 819.
  • 8Raphael SJ, McKeown-Eyssen G, Asa SL, et al. High-molecularweight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumours. Mod Pathol, 1994, 7(3): 295 -300.
  • 9Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol, 2001, 116(5): 696 -702.
  • 10Chan JK,Tsang WY.Endocrine malignancies that may mimic benign lesions[J].Semin Diagn Pathol,1995,12(1 ):45-63.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部